The TransEnterix Investors That Took the Biggest Hit After FDA’s Rejection

When Research Triangle Park-based TransEnterix, Inc. (NYSE MKT: TRXC) reached a deal to acquire the surgical robotics division of Italian health care company Sofar S.p.A., the foreign company made a bet on TransEnterix as well.

The $100 million deal included cash, but also a significant amount stock. Enough to make Sofar the largest single TransEnterix shareholder by far.